Expert Consensus Recommendations for Risk-Adapted Management of Myeloproliferative Neoplasms 2026

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are clonal hematopoietic disorders, with ET representing the most common Philadelphia chromosome–negative MPN in Korea. Since the previous Korean MPN guideline was published in 2020, the field has advanced considerably: diagnostic criteria have been further refined, the molecular landscape informing prognosis and treatment decisions has broadened, and new agents have become available. These developments have created a need to update the previous recommendations for the Korean clinical context. These expert consensus recommendations were developed by the Korean Society of Hematology MPN working Party to provide practical, evidence-informed recommendations for the risk-adapted management of PV, ET, and MF in Korean clinical practice. Recommendations are based on a comprehensive review of current international guidelines, including those of the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN), alongside emerging data from Korean and Asian patient populations. They address risk stratification frameworks, treatment goals evolving from hematologic response toward molecular response, and therapeutic options including phlebotomy, aspirin, cytoreductive agents, and allogeneic hematopoietic stem cell transplantation. Special clinical situations, including MPN in pregnancy and advanced-phase disease (accelerated and blast phase), are also addressed. These recommendations aim to support individualized, biology-informed treatment decisions, and to facilitate the integration of evolving therapeutic strategies into routine Korean hematology practice.

Authors

Institutions

Publication Details

Journal
Cancer Research and Treatment
Published
2026-11-18
DOI
https://doi.org/10.4143/crt.2026.0979
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expert Consensus Recommendations for Risk-Adapted Management of Myeloproliferative Neoplasms 2026

Chul Won Jung, Seug Yun Yoon, Soo‐Mee Bang, Seongsoo Jang et al.
Cancer Research and Treatment
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Expert Consensus Recommendations for Risk-Adapted Management of Myeloproliferative Neoplasms 2026

Chul Won Jung, Seug Yun Yoon, Soo‐Mee Bang, Seongsoo Jang, Yeung‐Chul Mun, Sung Hwa Bae, Haerim Chung, Chul Won Choi, Sung‐Eun Lee, Ho Young Kim, Seung‐Hyun Nam, Eun‐Ji Choi, Jong-Ho Won, Jinny Park, Junshik Hong, Ho Cheol Jang, Soo-Jeong Kim, Min Kyoung Kim, Sung-Hyun Kim, Ho-Jin Shin, Sung-Yong Kim
article en

Abstract

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are clonal hematopoietic disorders, with ET representing the most common Philadelphia chromosome–negative MPN in Korea. Since the previous Korean MPN guideline was published in 2020, the field has advanced considerably: diagnostic criteria have been further refined, the molecular landscape informing prognosis and treatment decisions has broadened, and new agents have become available. These developments have created a need to update the previous recommendations for the Korean clinical context. These expert consensus recommendations were developed by the Korean Society of Hematology MPN working Party to provide practical, evidence-informed recommendations for the risk-adapted management of PV, ET, and MF in Korean clinical practice. Recommendations are based on a comprehensive review of current international guidelines, including those of the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN), alongside emerging data from Korean and Asian patient populations. They address risk stratification frameworks, treatment goals evolving from hematologic response toward molecular response, and therapeutic options including phlebotomy, aspirin, cytoreductive agents, and allogeneic hematopoietic stem cell transplantation. Special clinical situations, including MPN in pregnancy and advanced-phase disease (accelerated and blast phase), are also addressed. These recommendations aim to support individualized, biology-informed treatment decisions, and to facilitate the integration of evolving therapeutic strategies into routine Korean hematology practice.

Cancer Research and Treatment
Ewha Womans University (KR), Seoul National University (KR), Yonsei University (KR), Konkuk University (KR), Soonchunhyang University (KR), Severance Hospital (KR), Dong-A University Hospital (KR), Soonchunhyang University Hospital Seoul (KR), Asan Medical Center (KR), Samsung Medical Center (KR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), Daegu Catholic University (KR), University of Ulsan (KR), Gachon University Gil Medical Center (KR), Daegu Catholic University Medical Center (KR), Konkuk University Medical Center (KR), Pusan National University Hospital (KR), Ewha Womans University Medical Center (KR), Chonnam National University Hwasun Hospital (KR), Yeungnam University Medical Center (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Yonsei University Health System (KR), Hallym University Medical Center (KR), Yeungnam University College (KR), Korea University Guro Hospital (KR), Yongin Severance Hospital (KR), Ewha Womans University Seoul Hospital (KR), Pusan National University (KR), Dong-A University (KR), Yeungnam University (KR), Sungkyunkwan University (KR), Catholic University of Korea (KR)
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon